Gray zone lymphoma: Better treated like hodgkin lymphoma or mediastinal large b-cell lymphoma?

Current Hematologic Malignancy Reports

Volumn 7, Issue 3, 2012, Pages 241-247

  Dunleavy, Kieron ^a   Grant, Cliona ^a   Eberle, Franziska C ^b   Pittaluga, Stefania ^a   Jaffe, Elaine S ^a   Wilson, Wyndham H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Chemotherapy; CHL NS; Classic Hodgkin lymphoma of the nodular sclerosis type; Diffuse large B cell lymphoma; DLBCL; Epigenetics; Gene expression profiling; Gray zone lymphoma; GZL; Hematologic malignancy; Hodgkin lymphoma; Hodgkin's disease; Immunophenotyping; Lymphomas; Mediastinal gray zone lymphoma; Mediastinal lymphoma; MGZL; Microenvironment; PMBL; Primary mediastinal large B cell lymphoma; Radiation therapy; Thymic B cell

Indexed keywords

BLEOMYCIN; CD20 ANTIGEN; CD23 ANTIGEN; CD30 ANTIGEN; CD45 ANTIGEN; CD79A ANTIGEN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 2; METHOTREXATE; OCTAMER TRANSCRIPTION FACTOR 2; PREDNISONE; PROCARBAZINE; PROTEIN BCL 6; TRANSCRIPTION FACTOR PAX5; VINBLASTINE; VINCRISTINE;

B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CELL INFILTRATION; CLASSICAL HODGKIN LYMPHOMA; CLINICAL FEATURE; CYTOPLASM; DRUG EFFICACY; EVENT FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; HODGKIN DISEASE; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHADENOPATHY; MEDIASTINAL GRAY ZONE LYMPHOMA; MEDIASTINAL LARGE B CELL LYMPHOMA; MEDIASTINUM TUMOR; MORPHOLOGY; NODULAR SCLEROSIS HODGKIN LYMPHOMA; ONSET AGE; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVIEW; SEX RATIO;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; HODGKIN DISEASE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MECHLORETHAMINE; MEDIASTINAL NEOPLASMS; PHENOTYPE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

EID: 84865962469     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-012-0130-5     Document Type: Review

References (57)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
2. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117 (19):5019-5032. The review discusses new concepts introduced in the 2008 WHO classification, including the concept of MGZL.
3. Grant C, Dunleavy K, Eberle FC, Pittaluga S, Wilson WH, Jaffe ES. Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do? Curr Hematol Malig Rep. 2011;6(3):157-63.
4. Rudiger T, Jaffe ES, Delsol G, et al. Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma). Ann Oncol. 1998;9 Suppl 5:S31-38.
5. Jaffe ES, Zarate-Osorno A, Medeiros LJ. The interrelationship of Hodgkin's disease and non-Hodgkin's lymphomas-lessons learned from composite and sequential malignancies. Semin Diagn Pathol. 1992;9(4):297-303.
6. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009;9(1):15-27.
7. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;184(4):1495- 505.
8. Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood. 2001;97(2):496-501.
9. Bellas C, Santon A, Manzanal A, et al. Pathological, immunological, and molecular features of Hodgkin's disease associated with HIV infection. Comparison with ordinary Hodgkin's disease. Am J Surg Pathol. 1996;20(12):1520-4.
10. Levine AM. Hodgkin's disease in the setting of human immunodeficiency virus infection. J Natl Cancer Inst Monogr. 1998;23:37-42.
11. Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005;29(11):1411-21.
12. Garcia JF, Mollejo M, Fraga M, et al. Large B-cell lymphoma with Hodgkin's features. Histopathology. 2005;47(1):101-10.
13. Schmid C, Pan L, Diss T, Isaacson PG. Expression of B-cell antigens by Hodgkin's and Reed-Sternberg cells. Am J Pathol. 1991;139(4):701-7.
14. Zukerberg LR, Collins AB, Ferry JA, Harris NL. Coexpression of CD15 and CD20 by Reed-Sternberg cells in Hodgkin's disease. Am J Pathol. 1991;139(3):475-83.
15. Loddenkemper C, Anagnostopoulos I, Hummel M, et al. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol. 2004;202(1):60-9.
16. Foss HD, Reusch R, Demel G, et al. Frequent expression of the Bcell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood. 1999;94(9):3108-13.
17. Lichtenstein AK, Levine A, Taylor CR, et al. Primary mediastinal lymphoma in adults. Am J Med. 1980;68(4):509-14.
18. Pileri SA, Zinzani PL, Gaidano G, et al. Pathobiology of primary mediastinal B-cell lymphoma. Leuk Lymphoma. 2003;44 Suppl 3: S21-26.
19. Moller P, Moldenhauer G, Momburg F, et al. Mediastinal lymphoma of clear cell type is a tumor corresponding to terminal steps of B cell differentiation. Blood. 1987;69(4):1087-95.
20. Pileri SA, Gaidano G, Zinzani PL, et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol. 2003;162 (1):243-53.
21. Higgins JP,Warnke RA. CD30 expression is common in mediastinal large B-cell lymphoma. Am J Clin Pathol. 1999;112(2):241-7.
22. Calaminici M, Piper K, Lee AM, Norton AJ. CD23 expression in mediastinal large B-cell lymphomas. Histopathology. 2004;45 (6):619-24.
23. Salama ME, Rajan Mariappan M, Inamdar K, Tripp SR, Perkins SL. The value of CD23 expression as an additional marker in distinguishing mediastinal (thymic) large B-cell lymphoma from Hodgkin lymphoma. Int J Surg Pathol. 2010;18(2):121-8.
24. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851-62.
25. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin's lymphoma. Blood. 2003 2003:2003-2006-1841.
26. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268-77.
27. Guiter C, Dusanter-Fourt I, Copie-Bergman C, et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood. 2004;104(2):543-9.
28. Melzner I, Bucur AJ, Bruderlein S, et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood. 2005;105(6):2535-42.
29. Oschlies I, Burkhardt B, Salaverria I, et al. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica. 2011;96(2):262-8.
30. Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471(7338):377-81.
31. Eberle FC, Salaverria I, Steidl C, et al. Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. Mod Pathol. 2011;24(12):1586-97.
32. Eberle FC, Rodriguez-Canales J, Wei L, et al. Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Haematologica. ;96(4):558-566. This is the first biologic study of GZLs. It provides insight into the plasticity of immunophenotype and morphology of these tumors, and their transitional appearance.
33. Bassal M, Mertens AC, Taylor L, et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006;24(3):476-83.
34. Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2011;117 (6):1806-1816. This study highlights the long-term complications of therapy, particulary radiation treatment in survivors of HL.
35. Dunleavy K, Bollard CM. Sobering realities of surviving Hodgkin lymphoma. Blood. 2011;117(6):1772-3.
36. Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 2010;28(8):1308-15.
37. Longo DL, Glatstein E, Duffey PL, et al. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. J Clin Oncol. 1997;15(11):3338-46.
38. Longo DL, Russo A, Duffey PL, et al. Treatment of advancedstage massive mediastinal Hodgkin's disease: the case for combined modality treatment. J Clin Oncol. 1991;9(2):227-35.
39. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104(12):3483-9.
40. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23 (21):4634-42.
41. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012;366(5):399-408. This recent study suggests that ABVD alone versus radiation-based therapy is associated with a better long-term outcome in limited-stage HL.
42. Dunleavy K, Mikhaeel G, Sehn LH, Hicks RJ, Wilson WH. The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma. Leuk Lymphoma. 2010;51 Suppl 1:28-33.
43. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPPABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348 (24):2386-95.
44. Zinzani PL, Martelli M, Magagnoli M, et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood. 1999;94 (10):3289-93.
45. Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer. 2004;90(2):372-6.
46. Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica. 2002;87(12):1258-64.
47. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328 (14):1002-6.
48. Hamlin PA, Portlock CS, Straus DJ, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol. 2005;130(5):691-9.
49. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-42.
50. Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006;17(1):123-30.
51. Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal Bcell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol. 2011;22(3):664-70.
52. Abramson J, Hellmann M, Feng Y, et al. High rate of initial treatment failure in patients with primary mediastinal B-cell lymphoma treated with R-CHOP. Blood. ASH Annual Meeting Abstracts 2011 118:1601.
53. Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol. 1993;11(8):1573-82.
54. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of doseadjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26(16):2717-24.
55. Wilson WH PP, Hurd D, et al. Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma (DLBCL)-CALGB 50103. Proc Am Soc Clin Oncol.
56. Dunleavy K, Pittaluga S, Shovlin M, et al. Untreated primary mediastinal B-cell (PMBL) and mediastinal grey zone (MGZL) lymphomas: comparison of biological features and clinical outcome following DA-EPOCH-R without radiation. Ann Oncol. 2011;22(4) Abstract 149.
57. Cazals-Hatem D, Andre M, Mounier N, et al. Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA study. Am J Surg Pathol. 2001;25(3):297-306.